What in the world am I doing up this late?
Oh, yeah. My anxiety is flaring. Big time.
But I had a good day today. It started out well. 702 more words
The European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) held a meeting December 9 – 11, 2014.
At this meeting, there are 22 positive opinions recommending the following medicines for designation as orphan medicinal products. 417 more words
Uplifting Athletes has plenty to celebrate in as we near the end of our seventh year as a national non-profit.
The continued support of our expanding coast-to-coast network of student-athlete led chapters is the main reason for our success. 397 more words
ArmaGen, a Calabasas, California-based clinical stage biotechnology company developing therapies for severe neurological disorders, announces December 11th, that the FDA’s Investigational New Drug (IND) application for the company’s lead product candidate, AGT-182 for Hunter Syndrome (Muchopolysaccharidosis II or MPS II), is accepted and is now active. 301 more words
On December 11th, The University of Connecticut’s Stem Cell Institute announces a stem cell research collaboration with Alexion Pharmaceuticals, to find new drug candidates for treating rare diseases. 240 more words
PTC Therapeutics receives FDA Orphan Drug Designation (ODD) on December 10th, for its lead product candidate, Translarna (Ataluren), for the treatment of Mucopolysaccharidosis Type I. 541 more words